Sanofi Loses Another Lovenox Round
This article was originally published in The Pink Sheet Daily
Executive Summary
“All options” under review in legal battle against generics.
You may also be interested in...
Safety Data Keeps Momenta/Sandoz’ Generic Lovenox In Play With FDA
Response to immunogenicity concern could boost chances for FDA approval next year.
Safety Data Keeps Momenta/Sandoz’ Generic Lovenox In Play With FDA
Response to immunogenicity concern could boost chances for FDA approval next year.
Lovenox Generics Might Be Slowed In U.S. Because Of EU Guidance, Sanofi Hopes
Sanofi-Aventis says an emerging European guideline prescribing clinical trials for low molecular weight heparin generics could sway FDA as it considers copies of its clot-busting blockbuster Lovenox